BioCentury | Aug 24, 2015
Clinical News

Addex preclinical data

In mice, 50 mg/kg oral dipraglurant led to anxiolytic effects in the elevated plus maze (EPM) test and the stress-induced hyperthermia (SIH) test. Additionally, 30 and 50 mg/kg dipraglurant led to antidepressant effects in the...
BioCentury | Dec 5, 2013
Targets & Mechanisms

A gut feeling about butyrate

Inflammatory bowel disease and other inflammatory conditions of the gut have long been associated with imbalances in mucosal levels of microflora-produced short-chain fatty acids such as butyrate and propionate, but the underlying mechanisms were unknown....
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Gastric cancer Focal adhesion kinase (FAK); Src Cell culture studies suggest the Enterolobium contortisiliquum-derived trypsin inhibitor EcTI could help treat gastric...
BioCentury | May 19, 2011
Distillery Therapeutics

Indication: Neurology

...PTG); epilepsy progressive myoclonus type 2A Lafora disease (laforin; EPM2A); NHL repeat containing 1 (NHLRC1; EPM2B...
...PTG could help treat Lafora disease, a teenage onset epilepsy disorder caused by EPM2A or EPM2B...
BioCentury | May 19, 2008
Clinical News

Rikelta brivaracetam: Phase III data

In a double-blind, placebo-controlled, international Phase III trial in about 56 patients, Rikelta missed the primary endpoint of symptom relief of action myoclonus. UCB Group (Euronext:UCB), Brussels, Belgium Product: Rikelta brivaracetam Business: Neurology Molecular target:...
BioCentury | Mar 25, 1996
Company News

Stanford University School of Medicine other research news

Researchers reported in Science that mutations in the gene encoding cystatin B are responsible for the primary defect in patients with progressive myoclonus epilepsy (EPM1), a rare, inherited form of epilepsy. Cystatin B is a...
Items per page:
1 - 6 of 6